Therapeutic potential of new antiinflammatory drugs

Epilepsia. 2011 Oct:52 Suppl 8:67-9. doi: 10.1111/j.1528-1167.2011.03242.x.

Abstract

Experimental and clinical findings have shown in the past decade that specific proinflammatory mediators and their cognate receptors are upregulated in epileptic brain tissue. In particular, the IL-1 receptor (R)/Toll-like receptor (TLR) signaling pathways are activated in experimental models of seizures and in human epileptic tissue from drug-resistant patients. Pharmacological targeting of these proinflammatory pathways using selective receptor antagonists, or the use of transgenic mice with perturbed cell signaling, demostrated that the activation of IL-1R type 1 and TLR4 by their respective endogenous ligands, i.e., interleukin (IL)-1b and High Mobility Group Box 1, is implicated in the precipitation and recurrence of experimentally induced seizures in rodents. This evidence highlights a new target system for pharmacological intervention to inhibit seizures by interfering with mechanisms involved in their genesis and recurrence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Anticonvulsants / therapeutic use*
  • Disease Models, Animal
  • Epilepsy / drug therapy*
  • Epilepsy / immunology
  • Humans
  • Mice
  • Mice, Transgenic
  • Receptors, Interleukin-1 / genetics
  • Receptors, Interleukin-1 / metabolism
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Toll-Like Receptor 4 / genetics
  • Toll-Like Receptor 4 / metabolism

Substances

  • Anti-Inflammatory Agents
  • Anticonvulsants
  • Receptors, Interleukin-1
  • TLR4 protein, human
  • Toll-Like Receptor 4